Skip to content

AbCellera Biologics Inc. ABCL Number of reportable segments

Number of reportable segments at other companies

Zymeworks logo
ZymeworksZYME
10.0%
ADMA Biologics logo
ADMA BiologicsADMA
2+300%
BioCryst Pharmaceuticals logo
BioCryst PharmaceuticalsBCRX
10.0%
Revvity logo
RevvityRVTY

Other financials

Income statement

See full
Revenue$8.3M+96.3%
Operating income-$57.5M+8.2%
Net income-$43.2M+5.4%
EPS (diluted)-$0.14+6.7%

Balance sheet

See full
Cash & equivalents$102.1M-44.6%
Total debt$140.2M+107%
Total equity$938.1M-8.3%
Total assets$1.3B-2.8%

Cash flow

See full
Operating cash flow-$33.5M-190%
CapEx$3.8M-64.0%
Free cash flow-$37.4M-68.3%

Valuation

See full
Market cap$1.72B+59.2%
Enterprise value$1.76B+100.0%
P/S21.7×-25.0×

Profitability

See full
Operating margin-267.6%-120pp
Net margin-181.7%-77.9pp
FCF margin-238.9%-90.9pp

Returns & leverage

See full
Return on equity-14.7%-0.8pp
Debt / equity0.1×+0.1×
Current ratio14.1×+3.9×

Where this comes from

Reported directly by AbCellera Biologics Inc. in its filing.

Tagged under the XBRL concept us-gaap:NumberOfReportableSegments.

The official record: AbCellera Biologics Inc.’s 10-K, filed February 24, 2026, on SEC EDGAR. View the filing →

Ask your AI about AbCellera Biologics Inc.'s number of reportable segments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is AbCellera Biologics Inc.'s number of reportable segments?
AbCellera Biologics Inc. (ABCL) reported number of reportable segments of 0.3 in Q4 2025.
What does number of reportable segments mean?
This metric indicates the number of distinct business units or geographic areas for which the company provides separate financial reporting. It reflects the complexity and organizational structure of the company's operations.